Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Gains from Sales and Divestitures: 2019-2024

Historic Gains from Sales and Divestitures for Eton Pharmaceuticals (ETON) over the last 5 years, with Dec 2024 value amounting to $90,402.

  • Eton Pharmaceuticals' Gains from Sales and Divestitures fell 6.86% to $84,204 in Q3 2025 from the same period last year, while for Sep 2025 it was $84,204, marking a year-over-year decrease of 6.86%. This contributed to the annual value of $90,402 for FY2024, which is 1.09% down from last year.
  • According to the latest figures from FY2024, Eton Pharmaceuticals' Gains from Sales and Divestitures is $90,402, which was down 1.09% from $91,402 recorded in FY2023.
  • Eton Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $91,402 for FY2023, and its period low was $7,595 during FY2020.
  • Over the past 2 years, Eton Pharmaceuticals' median Gains from Sales and Divestitures value was $90,902 (recorded in 2023), while the average stood at $90,902.
  • Data for Eton Pharmaceuticals' Gains from Sales and Divestitures shows a maximum YoY slumped of 97.57% (in 2020) over the last 5 years.
  • Eton Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $7,595 in 2020, then remained steady at $7,595 in 2021, then reached $91,402 in 2023, then fell by 1.09% to $90,402 in 2024.